Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 14, 2021

Primary Completion Date

January 23, 2024

Study Completion Date

July 19, 2024

Conditions
Chronic Hepatitis B
Interventions
DRUG

Tenofovir Alafenamide

Administered as film-coated oral tablets

DRUG

VIR-2218

Administered as a sub-cutaneous (SC) injection

DRUG

Nivolumab

Administered intravenously

DRUG

Selgantolimod

Administered as film-coated oral tablets

Trial Locations (26)

1010

Auckland City Hospital, Grafton

2170

Liverpool Hospital, Liverpool

2650

Hvidovre Hospital, Hvidovre

3050

Royal Melbourne Hospital, Parkville

8200

Aarhus University Hospital, Aarhus N

10330

Thai Red Cross AIDS Research Centre (HIV-NAT), Bangkok

10400

Ramathibodi Hospital, Bangkok

10700

Siriraj Hospital, Bangkok

50200

Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital, Muang

119228

National University Hospital, Singapore

529889

Changi General Hospital, Singapore

DK9000

Aalborg University Hospital, Aalborg

DK5000

Odense University Hospital, Odense

Unknown

Princess Margaret Hospital (Hong Kong), Hong Kong

Queen Mary Hospital, Hong Kong

Prince of Wales Hospital, Shatin

Alice Ho Miu Ling Nethersole Hospital, Tai Po

Singapore General Hospital, Singapore

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul Saint Mary Hospital, Seoul

06973

Chung-Ang University Hospital, Seoul

120-752

Yonsei University Severance Hospital, Seoul

152-703

Korea University Guro Hospital, Seoul

SE5 9RS

King's College Hospital NHS Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Vir Biotechnology, Inc.

INDUSTRY

lead

Gilead Sciences

INDUSTRY